-
Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk of preeclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, ElKhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2014;44:402-10. pdf -
First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014;34:618-27. pdf -
Maternal and foetal angiogenic imbalance in congenital heart defects.
Llurba E, Sánchez O, Ferrer Q, Nicolaides KH, Ruíz A, Domínguez C, Sánchez-de-Toledo J, García-García B, Soro G, Arévalo S, Goya M, Suy A, Pérez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L.
Eur Heart J 2014;35:701-7. -
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:34-40. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013;33:149-55. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
First trimester maternal serum free ß-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
Savvidou M, Syngelaki A, Muhaisen M, Emelyanenko E, Nicolaides KH.
BJOG 2012;119:410-6. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
First-trimester screening for neural tube defects using alpha-fetoprotein.
Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH.
Fetal Diagn Ther 2012;31:109-14. -
Temporal effect of Afro-Caribbean race on serum pregnancy-associated plasma protein-a at 9-13 weeks' gestation in screening for aneuploidies.
Ball S, Wright D, Sodre D, Lachmann R, Nicolaides KH.
Fetal Diagn Ther 2012;31:162-9. -
First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies.
Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH.
Fetal Diagn Ther 2011;30:194-202. -
First-trimester markers of aneuploidy in women positive for HIV.
Savvidou M, Samuel I, Syngelaki A, Poulton M, Nicolaides K.
BJOG 2011;118:844-8. -
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011;31:58-65. -
First-trimester prediction of macrosomia.
Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;29:139-47. -
A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester.
Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K.
Ultrasound Obstet Gynecol 2011;37:38-47. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16.